Document is current
Any future updates will be listed below
-
Authors
Fuller, Douglas S. https://orcid.org/0000-0002-2448-5896
Hallett, David
Dluzniewski, Paul J.
Fouqueray, Bruno
Jadoul, Michel
Morgenstern, Hal
Port, Friedrich K.
Tentori, Francesca
Pisoni, Ronald L.
-
Funding
Funding for this research was provided by:
Amgen
AstraZeneca Pharmaceuticals LP
Baxter Healthcare Corporation
European Renal Association-European Dialysis & Transplant Association
Fresenius Medical Care Asia-Pacific Ltd
Fresenius Medical Care Canada Inc
German Society of Nephrology (DGfN), Italian Society of Nephrology
Janssen Pharmaceuticals
Japanese Society for Peritoneal Dialysis
Keryx Biopharmaceuticals, Inc
Kidney Care UK
Kyowa Hakko Kirin
MEDICE Arzneimittel Pütter GmbH & Co K
Otsuka America Pharmaceutical
Proteon Therapeutics, Inc
The Association of German Nephrology Centres
Vifor Fresenius Medical Care Renal Pharma Ltd
- License Information
-
More Information
Article History
Received: 22 August 2018
Accepted: 24 April 2019
First Online: 14 May 2019
Ethics approval and consent to participate
: DOPPS was approved by a central institutional review board (IRB) in the US, Ethical and Independent Review Services, with additional IRB study approval and written patient consent obtained to meet national and local ethics committee regulations at each study site.
: Not applicable.
: PJD and BF are employees and stockholders of Amgen, Inc.; DH is a contingent worker hired by Amgen, Inc. and an employee of Simulstat, Inc.; MJ has received research grants from, and is a member of the speaker’s bureau for, Amgen, Inc.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
